Flexible Dosing Schedule with BESIVANCE

BESIVANCE® (besifloxacin ophthalmic suspension) 0.6% 5 mL bottle and packaging

Instill one drop in the affected eye(s) 3 times a day, 4 to 12 hours apart, for 7 days.¹ This dosing schedule may be convenient for pediatric patients.

Dosing schedule of one drop in the affected eye when waking, after school or work, and at bedtime may be convenient especially for pediatric patients

BESIVANCE demonstrates long-lasting tear concentrations² that allow for flexible dosing intervals between 4 and 12 hours.¹

BESIVANCE is available in a 5 mL bottle (NDC 242208-446-05).¹

Storage & Handling¹

Store at 15°C-25°C (59°F-77°F)
Protect from light
Invert closed bottle and shake once before use

REGISTER FOR UPDATES

Get additional information and resources.

Interested in BESIVANCE samples?

Requesting samples is easy.

Order samples

Indication

BESIVANCE^® (besifloxacin ophthalmic suspension) 0.6% is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans*, CDC coryneform group G, Corynebacterium pseudodiphtheriticum*, Corynebacterium striatum*, Haemophilus influenzae, Moraxella catarrhalis*, Moraxella lacunata*, Pseudomonas aeruginosa*, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis*, Staphylococcus lugdunensis*, Staphylococcus warneri*, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarius*

*Efficacy for this organism was studied in fewer than 10 infections.

Important Safety Information

BESIVANCE is not for injection into the eye.
As with other anti-infectives, prolonged use of BESIVANCE may result in overgrowth of non-susceptible organisms, including fungi. If super-infection occurs, discontinue use and institute alternative therapy.
Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis or during the course of therapy with BESIVANCE.
The most common adverse event reported in approximately 2% of patients treated with BESIVANCE was conjunctival redness. Other adverse events reported in patients receiving BESIVANCE occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.
Safety and effectiveness in infants below one year of age have not been established.

Click here for full Prescribing Information for BESIVANCE.

References: 1. BESIVANCE [package insert]. Tampa, FL: Bausch & Lomb Incorporated; 2018. 2. Data on file. Bausch & Lomb Incorporated.

Indication

*Efficacy for this organism was studied in fewer than 10 infections.

Important Safety Information

BESIVANCE is not for injection into the eye.
As with other anti-infectives, prolonged use of BESIVANCE may result in overgrowth of non-susceptible organisms, including fungi. If super-infection occurs, discontinue use and institute alternative therapy.
Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis or during the course of therapy with BESIVANCE.
The most common adverse event reported in approximately 2% of patients treated with BESIVANCE was conjunctival redness. Other adverse events reported in patients receiving BESIVANCE occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.
Safety and effectiveness in infants below one year of age have not been established.

Click here for full Prescribing Information for BESIVANCE.

THIS WEBSITE IS INTENDED FOR U.S. HEALTHCARE PROFESSIONALS ONLY.

Please choose an option below: